Claude LeDuc, the Co-Founder and President-CEO of RNA Technologies & Therapeutics, is a visionary leader in the field of Biopharma. With an impressive 36-year track record of international experience and accomplishments in both private and Fortune 500 companies, Claude has been a driving force behind the success of various organizations.
Claude’s journey in the pharmaceutical industry began at Syntex Labs, where he held diverse roles in sales, marketing. He then moved on to Serono Labs and Biomatrix-Genzyme RNA T&T, further enriching his expertise in international business development and knowledge in the industry.
As a serial entrepreneur and investor, Claude possesses a unique ability to identify promising opportunities and build successful ventures. Throughout his career, he has led teams through various development stages, from early R&D and preclinical programs to successful market launches at BioSyntech, Skeltex Technologies, Axcellon Biopolymers, MRM Proteomics, RNA T&T and Ortho Regenerative Technologies.’
One of Claude’s remarkable strengths lies in his exceptional fundraising capabilities. Under his leadership as CEO of multiple start-ups, he has raised more than $70M+ in equity and debenture notes in private and public settings, demonstrating his financial acumen and strategic accuity.
Claude’s unwavering passion for innovation and cutting-edge technologies has driven him to co-found RNA Technologies & Therapeutics. As President-CEO, he spearheads the company’s mission to revolutionize healthcare and improve patients’ lives through groundbreaking mRNA-based therapies.